ReShape Lifesciences Inc.

NasdaqCM:RSLS Stock Report

Market Cap: US$3.2m

ReShape Lifesciences Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Paul Hickey

Chief executive officer

US$506.4k

Total compensation

CEO salary percentage73.7%
CEO tenure2.3yrs
CEO ownershipn/a
Management average tenure2.4yrs
Board average tenure6.5yrs

Recent management updates

Recent updates

It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

Apr 18
It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

ReShape wins FDA clearance for device used in weight loss surgery

Aug 10

Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Mar 31
Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Dec 09
Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

Aug 24
Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

CEO Compensation Analysis

How has Paul Hickey's remuneration changed compared to ReShape Lifesciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$7m

Jun 30 2024n/an/a

-US$9m

Mar 31 2024n/an/a

-US$11m

Dec 31 2023US$506kUS$373k

-US$11m

Sep 30 2023n/an/a

-US$26m

Jun 30 2023n/an/a

-US$35m

Mar 31 2023n/an/a

-US$41m

Dec 31 2022US$158kUS$133k

-US$46m

Compensation vs Market: Paul's total compensation ($USD506.42K) is about average for companies of similar size in the US market ($USD646.54K).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.

CEO

Paul Hickey (59 yo)

2.3yrs

Tenure

US$506,416

Compensation

Mr. Paul F. Hickey is Chief Executive Officer, President and Director at ReShape Lifesciences Inc. from August 15, 2022. He served as Senior Vice President of Marketing and Reimbursement at EnteroMedics In...

Leadership Team

NamePositionTenureCompensationOwnership
Dan Gladney
Executive Chair9.1yrsUS$129.50k0.0021%
$ 68.1
Paul Hickey
CEO, President & Director2.3yrsUS$506.42kno data
Thomas Stankovich
Senior VP & CFO5.2yrsUS$307.12k0.00098%
$ 31.8
Mark Knudson
Co-Founder and Special Advisor to the CEOno dataUS$37.50kno data
Katherine Tweden
Co-Founderno dataUS$279.30kno data
Al Diaz
Vice President of Operations and R&D3.3yrsno datano data
Dov Gal
VP of Regulatory Clinical Quality & Compliance Officerno datano datano data
Jody Dahlman
Director of Communicationsno datano datano data
Naqeeb Ansari
Senior Vice President of Global Commercial Operations2.3yrsUS$1.16mno data

2.4yrs

Average Tenure

63yo

Average Age

Experienced Management: RSLS's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Dan Gladney
Executive Chair9.1yrsUS$129.50k0.0021%
$ 68.1
Paul Hickey
CEO, President & Director2.3yrsUS$506.42kno data
Ardaeviraf Minocherhomjee
Independent Director6.3yrsUS$52.50kno data
Gary Blackford
Independent Lead Director8.3yrsUS$77.00kno data
Philip Schauer
Member of Scientific Advisory Board6.5yrsno datano data
Caroline Apovian
Member of Scientific Advisory Board1.8yrsno datano data
Scott Shikora
Member of Scientific Advisory Board6.5yrsUS$892.19kno data
Lori McDougal
Independent Director9.4yrsUS$57.50kno data
Jaime Ponce
Member of Scientific Advisory Board6.5yrsno datano data
John Morton
Member of Scientific Advisory Board6.5yrsno datano data
Natan Zundel
Member of Scientific Advisory Board6.5yrsno datano data
Michael Baptista
Member of Scientific Advisory Board1.8yrsno datano data

6.5yrs

Average Tenure

66yo

Average Age

Experienced Board: RSLS's board of directors are considered experienced (6.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 09:22
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ReShape Lifesciences Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William PlovanicCanaccord Genuity
Matthew HewittCraig-Hallum Capital Group LLC
Jeffrey CohenLadenburg Thalmann & Company